Recent Business Highlights Completed initial public offering (IPO) In February, Metsera completed an IPO, raising approximately $316.2 million in aggregate gross proceeds from the offering before ...

In February, Metsera completed an IPO ... in professional and consulting fees as we prepared for our initial public offering and an increase in personnel-related expenses as we expanded our ...

In February, Metsera completed an IPO ... in professional and consulting fees as we prepared for our initial public offering and an increase in personnel-related expenses as we expanded our ...

In February, Metsera completed an IPO ... increased primarily due to increases in professional and consulting fees as we prepared for our initial public offering and an increase in personnel-related ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.

said on Wednesday that it is targeting a valuation of up to $2.6 billion in its New York initial public offering as the defense and space systems maker looks to take advantage of an expanding market.

Odyssey Therapeutics and Sionna Therapeutics have filed to carry out initial public offerings (IPOs ... in the footsteps of obesity drug developer Metsera and genetic medicines developer Maze ...

Metsera also closed its initial public offering in February 2025, generating gross proceeds of $316.2 million and aggregate net proceeds of $288.4 million. Metsera outlined its plans to utilize its ...

NEW YORK (AP) — The following is a list of initial public offerings planned for the coming week. Sources include IPO ETF manager Renaissance Capital, and SEC filings.